Skip to main content
Clinical Trials/NCT02586142
NCT02586142
Completed
Phase 3

Botulinum Toxin Injections by Ultrasounds Guidance and Stretching Exercise in Spastic Toe Clawing

Chang Gung Memorial Hospital1 site in 1 country30 target enrollmentAugust 2010

Overview

Phase
Phase 3
Intervention
Botulinum Toxin Type A
Conditions
Cerebrovascular Accident
Sponsor
Chang Gung Memorial Hospital
Enrollment
30
Locations
1
Primary Endpoint
Spasticity severity scale
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Claw toes deformity result in spasticity often seem in patients with central nerve disease. It also cause pressure sore in foot and pain during walking that didn't well improve under traditional treatment. There are few relative reports about the Botulinum toxin type A (BTX-A) injection on claw toe. The investigators' study has two main purposes:

  1. assess the efficiency of BTX-A injection under ultrasonographyic guidance on improving lower extremities function, pain and spasticity in patients with symptomatic claw toes.
  2. assess if regular stretching exercise can strength the efficiency of BTX-A injection on improving lower extremities function, pain and spasticity.

Detailed Description

The investigators will enroll 50 hemiplegic stroke patients met the inclusion criteria(onset more than 6 month, lower extremity Brunnstrome stage more than stage IV, walking without assistance devices and pain during walking due to claw toe. The investigators will focus and inject BTX-A with ultrasonographyic guidance on flexor digitorum longus and brevis(both 50 unit). If patients combine ankle plantar flexors spasticity, the investigators will inject another 50 unit on both the medial and lateral head of gastrocnemius . Every patients will receive regular stretching exercise in hospital and do self stretching exercise at home for 3 months after injection. Patients will be evaluated at 2 weeks, 4 weeks and 12 weeks, 24 weeks and 1 year after injection. Outcome measure include severity of spasticity and pain, sensory and motor function, range of motion, functional assessment of lower extremity and analyze pressure under foot.

Registry
clinicaltrials.gov
Start Date
August 2010
End Date
July 2013
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Chang Gung Memorial Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient with spasticity toe clawing(metatarsophalange jointextension, proximal and distal phalange joint flexion)
  • MAS scale of metatarsophalange joint and interphalangeal joint more than 2
  • Pain during walking, abnormal gait patterns and can't wear shoess due to claw toe
  • Haven't received botox or phenol or alcohol injections before

Exclusion Criteria

  • Lower extremities joint contrature, bone deformity
  • Had received botox injections or phenol injections or before due to lower extremities spasticity
  • Combine other neuromuscular system disease
  • Severe cognition disorder or aphasia after stroke
  • Significant atrophy of flexor digitorum longus and brevis
  • Allergy to botox
  • Infection on injection site
  • Have systemic infection
  • Now accept aminioglycoside or other medicine will affect neuromusclar transition

Arms & Interventions

Botulinum toxin type A(BTX-A) injection

To inject Botulinum toxin type A on the spasticity lower extremities for participants by ultrasounds guidance.

Intervention: Botulinum Toxin Type A

BTX-A injection plus stretching exercise

Inject Botulinum toxin type A on the spasticity lower extremity for participants by ultrasounds guidance. After injection, arrange them to receive stretching exercise in Kaoshiung Chang Gung Memorial Hospital 3 time per week for 3 months.

Intervention: Botulinum Toxin Type A

BTX-A injection plus stretching exercise

Inject Botulinum toxin type A on the spasticity lower extremity for participants by ultrasounds guidance. After injection, arrange them to receive stretching exercise in Kaoshiung Chang Gung Memorial Hospital 3 time per week for 3 months.

Intervention: Stretching exercise

Outcomes

Primary Outcomes

Spasticity severity scale

Time Frame: Change from Baseline data at 1 year

patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection 0=none, 1=mild, 2= median, 3=severe

Secondary Outcomes

  • Sensory function scale(Change from Baseline data at 1 year)
  • Modified Ashworth scale(MAS)(Change from Baseline data at 1 year)
  • Pain severity measurement recorded by VAS(Change from Baseline data at 1 year)
  • To develop a questionnaire (ABILOCO questionnaire)(Change from Baseline data at 1 year)
  • Brunnstrome stage(Change from Baseline data at 1 year)
  • Manual muscle test(Change from Baseline data at 1 year)
  • Functional ambulation classification scale(Change from Baseline data at 1 year)
  • Active range of motion measured by goniometer(Change from Baseline data at 1 year)
  • Berg Balance test(Change from Baseline data at 1 year)
  • Get up and go test(Change from Baseline data at 1 year)
  • 10-meter walking test(Change from Baseline data at 1 year)
  • Fugl-Meyer Assessment(Change from Baseline data at 1 year)
  • Barthel Index(Change from Baseline data at 1 year)
  • 6 minute walking test(Change from Baseline data at 1 year)

Study Sites (1)

Loading locations...

Similar Trials